2,15-dicyclopropyl-hexadecanedioic acid | 1365571-66-9

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 2,15-dicyclopropyl-hexadecanedioic acid
• 英文别名: Wjp2hbu8UU；1-[12-(1-carboxycyclopropyl)dodecyl]cyclopropane-1-carboxylic acid
• CAS: 1365571-66-9
• 化学式: C₂₀H₃₄O₄
• 分子量: 338.488
• InChiKey: KMDNTTRTPDGHSX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6
• 重原子数：
  24
• 可旋转键数：
  15
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  74.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2,15-dicyclopropyl-hexadecanedioic acid 在 dimethyl sulfide borane 、 水 、 氯化铵 作用下， 以 四氢呋喃 为溶剂， 反应 5.17h， 以81.9%的产率得到{1-[12-(1-Hydroxymethyl-cyclopropyl)-dodecyl]-cyclopropyl}-methanol
  参考文献：
  名称：

  METHODS AND COMPOSITIONS FOR TREATMENT OF DIABETES AND DYSLIPIDEMIA

  摘要：

  该发明涉及一种新型化合物的公式I：以及其立体异构体和/或药用盐，用于治疗糖尿病和与糖尿病相关的血脂异常。

  公开号：

  US20120071528A1
• 作为产物：
  描述：

  Tert-butyl 1-[12-[1-[(2-methylpropan-2-yl)oxycarbonyl]cyclopropyl]dodecyl]cyclopropane-1-carboxylate 在 甲酸 作用下， 反应 16.0h， 生成 2,15-dicyclopropyl-hexadecanedioic acid
  参考文献：
  名称：

  METHODS AND COMPOSITIONS FOR TREATMENT OF DIABETES AND DYSLIPIDEMIA

  摘要：

  该发明涉及一种新型化合物的公式I：以及其立体异构体和/或药用盐，用于治疗糖尿病和与糖尿病相关的血脂异常。

  公开号：

  US20120071528A1

文献信息

• Substituted cycloalkanes for managing nephrogenic diabetes insipidus
  申请人：NephroDI Therapeutics, Inc.

  公开号：US11179354B2

  公开（公告）日：2021-11-23

  In certain embodiments, this disclosure relates to methods of treating or preventing nephrogenic diabetes insipidus comprising administering an effective amount of a compound of Formula (I) or derivatives thereof, as described herein, to a subject in need thereof. In certain embodiments, the subject has been diagnosed with nephrogenic diabetes insipidus.

  在某些实施方案中，本公开涉及治疗或预防肾源性糖尿病的方法，包括向有需要的受试者施用有效量的如本文所述的式(I)化合物或其衍生物。在某些实施方案中，受试者已被诊断为肾源性糖尿病。
• Managing Nephrogenic Diabetes Insipidus
  申请人：Emory University

  公开号：US20200383940A1

  公开（公告）日：2020-12-10

  In certain embodiments, this disclosure relates to methods of treating or preventing nephrogenic diabetes insipidus comprising administering an effective amount of a compound of Formula (I) or derivatives thereof, as described herein, to a subject in need thereof. In certain embodiments, the subject has been diagnosed with nephrogenic diabetes insipidus.
• SUBSTITUTED CYCLOALKANES FOR MANAGING NEPHROGENIC DIABETES INSIPIDUS
  申请人：NephroDI Therapeutics, Inc.

  公开号：US20220031639A1

  公开（公告）日：2022-02-03

  In certain embodiments, this disclosure relates to methods of treating or preventing nephrogenic diabetes insipidus comprising administering an effective amount of a compound of Formula I or derivatives thereof, as described herein, to a subject in need thereof. In certain embodiments, the subject has been diagnosed with nephrogenic diabetes insipidus.
• US8623897B2
  申请人：——

  公开号：US8623897B2

  公开（公告）日：2014-01-07
• [EN] METHODS AND COMPOSITIONS FOR TREATMENT OF DIABETES AND DYSLIPIDEMIA<br/>[FR] PROCÉDÉS ET COMPOSITIONS POUR LE TRAITEMENT DU DIABÈTE ET DE LA DYSLIPIDÉMIE
  申请人：KAREUS THERAPEUTICS SA

  公开号：WO2012040177A1

  公开（公告）日：2012-03-29

  Novel compounds of Formula I are provided: its stereoisomers and/or pharmaceutically acceptable salts for the treatment of diabetes and diabetes-associated dyslipidemia, wherein R1 is selected from a group consisting of hydroxy, alkoxy, amine, alkyl, haloalkyl, NHSO2R, or NHCOR wherein R is selected from alkyl or cycloalkyl, NHR' wherein R' is alkyl or cycloalkyl optionally substituted by hydroxy or alkoxy; and n1 and n2 are independently selected from 0, 1, and 2. At least one of R3 and R4 and/or R5 and R6 form a cyclic ring of 3-8 carbon atoms optionally containing alkyl groups, hetero atoms, or functional groups such as O, N, SO2. Additionally, when R3 and R4 or R5 and R6 do not form a cyclic ring, then they may be independently selected from hydrogen, alkyl, branched alkyl, and cycloalkyl. L1 is a linear aliphatic chain optionally containing from 4 to 16 carbon atoms. The chain may optionally be substituted one or more times by alkyl, branched alkyl, cycloalkyl, or aryl. R2 is independently selected from hydrogen, alkoxy, hydroxy, alkyl, haloalkyl, cycloalkyl, heterocycloalkyl, heteroaryl, cyano, or COR7, wherein R7 is selected from hydroxy, alkyl, alkoxy, or amine, NHR', NHSO2R, or NHCOR. Y1 is oxygen or hydrogen. Y2 is optional, wherein when Y2 is present, Y1 and Y2 are hydrogen. When Y2 is not present, Y1 is a carbonyl group.